Market Cap 7.32M
Revenue (ttm) 0.00
Net Income (ttm) -4.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 199,100
Avg Vol 116,024
Day's Range N/A - N/A
Shares Out 3.14M
Stochastic %K 85%
Beta -0.27
Analysts Sell
Price Target $42.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
LowFloatScanner_
LowFloatScanner_ Oct. 24 at 8:26 PM
What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $JAGX $HCTI $ALZN $BBAI ---
0 · Reply
Asrm088
Asrm088 Oct. 24 at 11:05 AM
$ALZN moving
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 22 at 3:35 PM
GIPR is set to be one of the most explosive small‑cap stories out there. With tangible real estate assets backing it and near‑zero dilution pressure, the foundation is built. The chart is showing signs of bottoming and a golden cross could be imminent. At current levels, the re‑rating potential toward double digits is real. $XELA $BIAF $SGH $ALZN
0 · Reply
hiwatt
hiwatt Oct. 22 at 1:10 PM
$ALZN In doing a followup to my previous post about lithium market, I did find where lithium is less than $20 a month, so I'm adjusting annual revenue back to $750M. I then looked at top 50 pharmas and their revenue to marketcap ratio. It ranges from 2 to 10. So let's be conservative a go with 2 x $750 =MC of $1.5B. Let's say Alzn gets a bump in price from current trial and with an annoucement of starting P2B BP trial at Harvard. and they do offering of 2M more shares. Then a future projected MC of $1,5B divided 6M shares = $250 a share. Here's another interesting tidbit about lithium. There is a lot of talk in the medical community saying lithium should be prescribed more than it is, because it is the "Gold Standard". It just has a toxicity issue. "IF" Alzn can remedy that and they price Al001 competitive with generic, then insurance (the gate keeper) would love to switch patients from a more expensive to a cheaper, better drug and that MC goes up even more(BP-US-7M) (WW 46M)
1 · Reply
Asrm088
Asrm088 Oct. 20 at 11:16 PM
$ALZN Lego 💥
0 · Reply
hiwatt
hiwatt Oct. 20 at 1:07 AM
$ALZN Assuming everything goes well with upcoming trial, Alzn may have an unique opportunity to move forward with bipolar. Most times when a biotech does a drug repurposing or reformulation, they have to set the prices high enough to cover development cost and provide a profit while the new drug slowing gains market revenue share. A recent example is testosterone. Both IV and gel testosterone were generic by the time 3 new oral versions got approved. The cost for oral was set so high, most couldn't afford out of pocket and insurance was reluctant to cover because of cheaper alternatives, even though oral is preferred by most. Generic lithium cost $20 a month plus $120 a year testing levels cost, estimated. If AL001 proves to be safer with better efficacy and doesn't require testing, Bingo! If they charge $30 a month, $360 a year x 3M patients=$1B. Doctors should switch out patients and insurance should cover.
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 17 at 9:24 PM
Watch VRME What’s rare a small cap with real cash cushion. As of mid 2025, VRME reportedly holds 17.2M in assets vs $2.7M in liabilities.  If value begins to show, this company has underrated balance sheet strength baked in. $RCAT $DLPN $ALZN $SGH
0 · Reply
hiwatt
hiwatt Oct. 14 at 9:50 PM
$ALZN Well considering Todd just sold over 900k B converted shares in the past 6 months, I assume this 8k filed eliminating convertable series B and C is a good thing.
1 · Reply
SimSimBola
SimSimBola Oct. 13 at 1:55 PM
$ALZN wtf is this??
0 · Reply
StockChiefs
StockChiefs Oct. 12 at 9:28 PM
Incase you guys missed the 900% GLTO run (1.2 mil float), Make sure add MTEX to your squeeze wathclists! Very nice after hours breakout - good momentum. Only 600k shares float. Holding some shares for a pre-market continuation run! Going by the float and strong support, It has the possiblity for a parabolic once volume enters MTEX recently ran +100% in After-Hours and now it is breaking out again ! Keep it on watch bulls! $MARA $JAGX $HCTI $ALZN news
0 · Reply
Latest News on ALZN
Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 6 months ago

Alzamend Neuro Announces Reverse Stock Split


See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 1:45 PM EDT - 4 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday


Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 11:54 AM EDT - 4 years ago

Why Alzamend Neuro Shares Are Surging Higher Today


Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 4 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today


Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 4 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering


LowFloatScanner_
LowFloatScanner_ Oct. 24 at 8:26 PM
What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $JAGX $HCTI $ALZN $BBAI ---
0 · Reply
Asrm088
Asrm088 Oct. 24 at 11:05 AM
$ALZN moving
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 22 at 3:35 PM
GIPR is set to be one of the most explosive small‑cap stories out there. With tangible real estate assets backing it and near‑zero dilution pressure, the foundation is built. The chart is showing signs of bottoming and a golden cross could be imminent. At current levels, the re‑rating potential toward double digits is real. $XELA $BIAF $SGH $ALZN
0 · Reply
hiwatt
hiwatt Oct. 22 at 1:10 PM
$ALZN In doing a followup to my previous post about lithium market, I did find where lithium is less than $20 a month, so I'm adjusting annual revenue back to $750M. I then looked at top 50 pharmas and their revenue to marketcap ratio. It ranges from 2 to 10. So let's be conservative a go with 2 x $750 =MC of $1.5B. Let's say Alzn gets a bump in price from current trial and with an annoucement of starting P2B BP trial at Harvard. and they do offering of 2M more shares. Then a future projected MC of $1,5B divided 6M shares = $250 a share. Here's another interesting tidbit about lithium. There is a lot of talk in the medical community saying lithium should be prescribed more than it is, because it is the "Gold Standard". It just has a toxicity issue. "IF" Alzn can remedy that and they price Al001 competitive with generic, then insurance (the gate keeper) would love to switch patients from a more expensive to a cheaper, better drug and that MC goes up even more(BP-US-7M) (WW 46M)
1 · Reply
Asrm088
Asrm088 Oct. 20 at 11:16 PM
$ALZN Lego 💥
0 · Reply
hiwatt
hiwatt Oct. 20 at 1:07 AM
$ALZN Assuming everything goes well with upcoming trial, Alzn may have an unique opportunity to move forward with bipolar. Most times when a biotech does a drug repurposing or reformulation, they have to set the prices high enough to cover development cost and provide a profit while the new drug slowing gains market revenue share. A recent example is testosterone. Both IV and gel testosterone were generic by the time 3 new oral versions got approved. The cost for oral was set so high, most couldn't afford out of pocket and insurance was reluctant to cover because of cheaper alternatives, even though oral is preferred by most. Generic lithium cost $20 a month plus $120 a year testing levels cost, estimated. If AL001 proves to be safer with better efficacy and doesn't require testing, Bingo! If they charge $30 a month, $360 a year x 3M patients=$1B. Doctors should switch out patients and insurance should cover.
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 17 at 9:24 PM
Watch VRME What’s rare a small cap with real cash cushion. As of mid 2025, VRME reportedly holds 17.2M in assets vs $2.7M in liabilities.  If value begins to show, this company has underrated balance sheet strength baked in. $RCAT $DLPN $ALZN $SGH
0 · Reply
hiwatt
hiwatt Oct. 14 at 9:50 PM
$ALZN Well considering Todd just sold over 900k B converted shares in the past 6 months, I assume this 8k filed eliminating convertable series B and C is a good thing.
1 · Reply
SimSimBola
SimSimBola Oct. 13 at 1:55 PM
$ALZN wtf is this??
0 · Reply
StockChiefs
StockChiefs Oct. 12 at 9:28 PM
Incase you guys missed the 900% GLTO run (1.2 mil float), Make sure add MTEX to your squeeze wathclists! Very nice after hours breakout - good momentum. Only 600k shares float. Holding some shares for a pre-market continuation run! Going by the float and strong support, It has the possiblity for a parabolic once volume enters MTEX recently ran +100% in After-Hours and now it is breaking out again ! Keep it on watch bulls! $MARA $JAGX $HCTI $ALZN news
0 · Reply
hiwatt
hiwatt Oct. 12 at 6:48 PM
$ALZN Below is the main reason I decided to invest in Alzn.---- The new research explains why: Amyloid beta was sequestering these other lithium compounds before they could work. Yankner and colleagues from Mass General Hospital found lithium orotate by developing a screening platform that searches a library of compounds for those that might bypass amyloid beta. Other researchers can now use the platform to seek additional amyloid-evading lithium compounds that might be even more effective.-----------------My son is a Psychiatrist that did his residency at Mass General Hospital and I know first hand the level of excellence and pride that exist at that institution. So to have them in partnership with Alzn on their phase 2B trials makes the risk worth the risk!
2 · Reply
NUTPOTL
NUTPOTL Oct. 10 at 9:36 PM
$ALZN That was my 3,500 share bid at $2.12 filled about 1,000 so far but will leave the remaining 2,500 up if someone wants to get shaken out just sell to me.
0 · Reply
NUTPOTL
NUTPOTL Oct. 10 at 6:00 PM
$ALZN Good to go from here just grabbed it 2.24.
0 · Reply
hiwatt
hiwatt Oct. 10 at 4:39 PM
$ALZN Todd shot his wad this morning!
2 · Reply
Guy592
Guy592 Oct. 10 at 12:26 AM
$GPUS All that i can say is, stay away from anything Todd Ault is in. $ALZN reverse split all the time. muln another big trash that changed their name. and this. I'm sure there are more.
1 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 10:49 PM
Keep a close watch on CMCT! $BGMS $ALZN $XHG $HIND
0 · Reply
hiwatt
hiwatt Oct. 9 at 6:15 PM
$ALZN Looking back on the message board, I found this message in July where Hyperscale Data planned to sell 939,281 shares of Alzn. As of yesterday, Todd has sold 784,365, leaving a balance of 154,916. If that's the case, he's about tapped out.
1 · Reply
VandeleyIndustries
VandeleyIndustries Oct. 9 at 5:30 PM
$ALZN been waiting for this piece of shizz to do something??WTF???
0 · Reply
hiwatt
hiwatt Oct. 9 at 12:10 PM
$ALZN The last update on clinical trials was 9-25-2025 which was the last person that met criteria finishing up the trial. Alzn estimated 30 days to publish results, but with Qmenta maintaining the paperwork and results, don't be surprised to see them sooner. Either way, should be in the next 2 weeks and hopefully stock price run up will intensify.---QMENTA’s cloud-based platform will manage and analyze medical imaging data throughout the trials, ensuring regulatory compliance, enhancing operational efficiency and supporting data management. Their advanced AI solutions will play a critical role in optimizing the imaging workflow across all five clinical studies.
0 · Reply
Stockboi_
Stockboi_ Oct. 8 at 5:31 PM
$ALZN show us
0 · Reply
JL_TradeZ
JL_TradeZ Oct. 8 at 3:00 PM
🚨(SPECIAL PLAY) $ALZN has been holding a tight base between 2.40 and 2.60 with a super small float of 2.5M and no debt. They’ve got about 5.6M in cash, so they’re fine on funding while the Phase II trials at Massachusetts General Hospital continue. The only thing holding it back right now is the insider selling, but once that slows down, it can run from there. If it breaks 2.58 with volume, we could see a nice squeeze happening soon PT: 2.80-3+ SL: 2.37
1 · Reply
Bulut21
Bulut21 Oct. 8 at 2:48 PM
0 · Reply